Merck & Co. Inc. (MRK) announced that in an investigational study, its medicine COZAAR or losartan potassium tablets 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR. The Merck-sponsored study compared the safety and efficacy of two doses of COZAAR in patients with chronic heart failure and reduced cardiac function (left ventricular ejection fraction) who were intolerant of angiotensin-converting enzyme or ACE inhibitors.
COZAAR is not indicated in the U.S. for the treatment of patients with chronic heart failure and is not approved for use, for any indication, at the 150 mg dose used in the Heart failure Endpoint evaluation of the A-II-Antagonist Losartan or HEAAL study.
COZAAR is an angiotensin II antagonist (AIIA), cardiovascular medicine approved for three indications:For the treatment of hypertension and may be used alone or in combination with other antihypertensive agents, including diruetics. to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, although there is evidence that this benefit does not apply to black patients. For the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. In this population, COZAAR reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.